Reply to the Editor:  by Lim, Eric
Letters to the
Editor
The Editor welcomes submissions for
possible publication in the Letters to the
Editor section that consist of commen-
tary on an article published in the Jour-
nal or other relevant issues. Authors
should:
● Include no more than 500 words of text,
three authors, and five references
● Type with double-spacing
● See http://jtcs.ctsnetjournals.org/misc/
ifora.shtml for detailed submission
instructions.
● Submit the letter electronically via
jtcvs.editorialmanager.com.
Letters commenting on an article pub-
lished in the JTCVS will be considered if
they are received within 6 weeks of the
time the article was published. Authors
of the article being commented on will be
given an opportunity to offer a timely
response (2 weeks) to the letter. Authors
of letters will be notified that the letter
has been received. Unpublished letters
cannot be returned.
TReasons for inability of clopidogrel
to inhibit platelet aggregation early
after coronary artery bypass surgery
To the Editor:
Clopidogrel administration for platelet in-
hibition after coronary artery surgery and
interventional cardiology is currently a
topic of much-deserved attention and de-
bate. I read with interest the recent article
in the Journal by Lim and colleagues.1 On
the basis of the results of an interim anal-
ysis of their prospective, double-blind, ran-
domized, controlled trial to compare the
efficacy of clopidogrel and aspirin as anti-
platelet agents, Lim and colleagues con-
clude that clopidogrel, unlike aspirin, did
not inhibit platelet aggregation in the first 5
postoperative days and therefore should not
be used as a sole antiplatelet agent early
after coronary surgery. According to the
authors, the ineffectiveness of clopidogrel
was an “unexpected” finding. However,
plenty of evidence is available from pub-
lished studies to suggest a logical explana-
tion for this unexpected finding.
Clopidogrel is a pro-drug, which is con-
verted to an active, unstable drug by cyto-
chrome P450 (CYP). The active drug irre-
versibly blocks 1 specific platelet: adenosine
5’-diphosphate receptor (P2Y12). It was re-
cently suggested that the most abundant hu-
man CYP isoform, 3A4, activates clopi-
dogrel.2 Certain lipophilic statins (ie,
simvastatin, atorvastatin, and lovastatin),
which are substrates of the CYP3A4 isoform,
competitively inhibit the metabolic activation
of clopidogrel. As a result, the relative clopi-
dogrel-induced platelet inhibition is dimin-
ished, especially if administered in a low
dose.3 Furthermore, clopidogrel administra-
tion results in interindividual variability in
platelet inhibition. This variable platelet inhi-
bition response to clopidogrel has been rec-
ognized by all who have tested clopidogrel
efficacy by platelet aggregometry and corre-
lates with CYP3A4 metabolic activity.4 In
addition, it is extremely important to remem-
ber that platelet inhibition by clopidogrel is
dose-related up to a dose of 400 mg and that
he Journal of Thoracic and Cardiovascularinhibition at a higher dose remains stable
from 2 to 72 hours.5
A closer look at the study by Lim and
colleagues1 clearly reveals that all of these
confounding factors are present and that
they influence the results of their interim
analysis. In my opinion, the conclusion of
this study would be different if a larger
dose of clopidogrel were used and nonre-
sponders (10%) and low responders
(20%), as well as those on statins, were
excluded.
Shahzad G. Raja, MRCS
Department of Cardiac Surgery
Royal Hospital for Sick Children
Yorkhill NHS Trust
Glasgow G3 8SJ
United Kingdom
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Reply to the Editor:
The opinion on the interaction between
statins and clopidogrel is still subject to
fierce debate.1,2 However, excluding sub-
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Letters to the Editorjects from the analysis because they are on
statins effectively excludes the majority of
patients undergoing coronary surgery. We
report that clopidogrel, unlike aspirin, did
not inhibit platelet aggregation in the first 5
postoperative days, a result that is applica-
ble to the wider population of patients ir-
respective of the eventual outcome of the
drug interaction debate.
Little consideration has been given to
the suggestion of excluding nonresponders
and low responders from the analysis. If we
did that for any arm of any trial only the
favorable responders would be left, giving
the false impression of treatment efficacy.
It is plausible that increasing the dose of
clopidogrel may increase antiplatelet ef-
fects in similar conditions (but this should
not be assumed). However, the current rec-
ommended dose is 75 mg per day, and a
loading dose of clopidogrel is only indi-
cated in unstable angina (300 mg single
loading dose).3 This information is consis-
tent with the product information sheet is-
sued by Sanofi-Synthelabo (New York,
NY).
Our aim was to report the results of an
intention-to-treat randomized clinical trial,
using approved drug doses, with findings
that can be generalized to the wide popu-
lation undergoing coronary surgery, not to
manipulate analyses to favor any particular
arm.
Eric Lim
Papworth Hospital
Cambridge
United Kingdom
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coronary sinus perfusion in off-pump
surgery
To the Editor:
I read with great interest the article by
Castella and Buckberg1on retrograde coro-
nary sinus perfusion in off-pump surgery.
My colleagues and I have been constantly
stimulated by the pioneering work of Dr
Buckberg on myocardial preservation. It is
indeed very gratifying and encouraging to
know that the technique we2 have been
using regularly since September 1997 to
perform off-pump coronary artery bypass
grafting (OPCABG) with no ischemia dur-
ing periods of construction of the distal
anastomosis has been proven by the very
elegant work of Castella and Buckberg1 to
be effective in reducing systolic and dia-
Figure 1. Technique of retrograde perfusion
coronary artery bypass grafting. A, Antegr
nary sinus cannula; S, stenosed coronary a
P, pressure monitoring line.
scular Surgery ● February 2005stolic dysfunction during periods of coro-
nary occlusion. In our technique, after mid-
sternotomy a retrograde coronary sinus
catheter is inserted and connected to an
antegrade cannula in the ascending aorta.2
Perfusion is now allowed through this route
from the aorta to the coronary sinus, on-
ward through the capillaries to the myocar-
dium, and out through the arterioles at the
site of ischemia. There is ample proof that
ischemia is relieved as evidenced by the
following facts: (1) reversion of electro-
cardiographic changes of ischemia, (2) vig-
orous backbleeding of dark blood on tem-
porary release of the distal snare after
arteriotomy, and (3) a good oxygen extrac-
tion ratio across the myocardium calculated
by sampling blood from the antegrade can-
nula and from the arteriotomy.3
ring combined carotid endarterectomy and
cardioplegia cannula; R, retrograde coro-
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